Drug Profile
GSK 2981710
Alternative Names: GSK2981710Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Ketones; Nootropics; Triglycerides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cognition disorders; Memory disorders
Most Recent Events
- 01 Jul 2015 GlaxoSmithKline completes a phase I trial in Cognition and Memory disorders in the United Kingdom (NCT01702480)
- 01 Nov 2012 Phase-I clinical trials in Cognition disorders (in patients aged 55 to 80 years) in United Kingdom (PO)
- 01 Nov 2012 Phase-I clinical trials in Memory disorders (in patients aged 55 to 80 years) in United Kingdom (PO)